Анализ факторов прогноза у больных раком мочевого пузыря II стадии

1. Поляков С.М., Левин Л.Ф., Шебеко Н.Г. Злокачественные новообразования в Беларуси, 1996–2005 гг. Под ред. А.А. Граковича, И.В. Залуцкого. Минск, БелЦМТ; 2006.

2. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001. с. 2–5.

3. Fujii Y., Kawakami S., Koga F. et al. Longterm outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92:559–62.

4. Zieger K., Wolf H., Olsen P.R., Hojgaard K. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. BJU Int 2000;85:824–8.

5. Borhan A., Reeder J.E., O'Connell M.J. Grade progression and regression in recurrent urothelial cancer. J Urol 2003;169:2106–9.

6. Soloway M., Bruck D.S., Kim S.S. Expectant management of small recurrent, non-invasive papillary bladder tumours. J Urol 2003;170:438–41.

7. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186–90.

8. Sengupta S., Blute M.L. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67(3 Suppl1):48–54.

9. Gospodarowicz M. Radiotherapy and Organ Preservation in Bladder Cancer: Are We Ignoring the Evidence? J Clin Oncol 2002;14:3048–50.

10. Quek M.L., Stein J.P., Daneshmand S. et al. A critical analysis of perioperative mortality from radical cystectomy. J Urol 2006;175: 886–90.

11. Novotny V., Hakenberg O.W., Wiessner D. et al. Perioperative complication of radical cystectomy in a contemporary series. Eur Urol 2007; 51:397–402.

12. Michaelson M.D., Shipley W.U., Heney N.M. et al. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer 2004; 90:578–81.

13. Rosenberg J.E., Carroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174:14–20.

14. Weizer A.Z., Joshi D., Daignault S. et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 2007;177:1287–93.

15. Sylvester R.J., van der Meijden A.P., Oosterlink W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77.

16. Palou J. Patient risk profiles: prognostic factors of recurrence and progression. Eur Urol Suppl 2006;5:648-53.

17. Wazait H.D., Al-Bhueissi S.Z., Patel H.R. et al. Long-term surveillance of bladder tumours: current practice in the United Kingdom and Ireland. Eur Urol 2003;43:485-8.

18. Leibovitch L., Ben-Chaim J., Ramon J. et al. The significance of urethral obstruction in invasive transitional cell carcinoma of the urinary bladder. J Surg Oncol 1993;52:31.

19. Wallace A. Superficial bladder cancer. Comprehensive Urology. Ed. by R.M. Weiss, N.J.R. George, P.H. O’Reily; 2001. p. 363-73.

20. Tinzl M., Marberger M. Urinary Markers for Detecting Bladder Cancer. EAU Update Series 2003;1(2):64-70.

21. Satoh E., Miyao N., Tachiki H. Prediction of muscle invasion of bladder cancer by cystoscopy J. Urol 2002;41:178–81.